建議您使用以下瀏覽器觀看本網站，
以獲得最佳瀏覽效果。
Pipeline
- Candidate
- Target/Mechanism
- Indication
- Partner
Discovery
Pre-Clinical
Phase I
Phase II
Phase III
IBI302
Inhibit complement activation and angiogenesis
Elderly (wet) macular degeneration (nAMD) patients
(world-wide)
AP203
T-cube BsAb
Non-small cell lung cancer, head and neck cancer, and esophageal cancer
Phase 1 (TWN) in progress
AP402
T-cube BsAb
breast cancer
IND filing (AUS) in November 2024
